Evidence map›Paper›PMID 40390157›Full record

ArticleInternational journal of dermatology2025

Epidemiology of Psoriasis in Poland: Prevalence, Incidence, and Mortality Rates.

Joanna Bartosińska, Jacek C Szepietowski, Dorota Raczkiewicz, Christopher E M Griffiths, Darren M Ashcroft, Alison K Wright, Krzysztof Podwójcic, Jakub Turcza, Michał Maluchnik, Agnieszka Chłoń-Domińczak and 1 more

Abstract read
In one paragraph

Article in International journal of dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Trial
  2. Medicina (Kaunas, Lithuania) · 2026
    Observational
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Joanna BartosińskaDepartment of Dermatology, Venereology and Pediatric Dermatology, Medical University of Lublin, Lublin, Poland.ORCID https://orcid.org/0000-0003-4106-3051
Jacek C SzepietowskiDivision of Dermatology, Venereology and Clinical Immunology, Faculty of Medicine, Wroclaw University of Science and Technology, Wroclaw, Poland.ORCID https://orcid.org/0000-0003-0766-6342
Dorota RaczkiewiczDepartment of Medical Statistics, School of Public Health, Centre of Postgraduate Medical Education, Warsaw, Poland.ORCID https://orcid.org/0000-0003-3517-6711
Christopher E M GriffithsCentre for Dermatology Research, The University of Manchester, Manchester, UK.ORCID https://orcid.org/0000-0001-5371-4427
Darren M AshcroftCentre for Pharmacoepidemiology and Drug Safety, Division of Pharmacy and Optometry, School of Health Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.ORCID https://orcid.org/0000-0002-2958-915X
Alison K WrightCentre for Pharmacoepidemiology and Drug Safety, Division of Pharmacy and Optometry, School of Health Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.ORCID https://orcid.org/0000-0002-8418-8332
Krzysztof PodwójcicInstitute of Labour and Social Studies, Warsaw, Poland.ORCID https://orcid.org/0000-0002-2902-8029
Jakub TurczaDepartment of Cosmetology and Aesthetic Medicine, Medical University of Lublin, Lublin, Poland.ORCID https://orcid.org/0009-0004-3609-8772
Michał MaluchnikMinistry of Health of the Republic of Poland, Warsaw, Poland.ORCID https://orcid.org/0000-0002-4482-498X
Agnieszka Chłoń-DomińczakInstitute of Statistics and Demography, Collegium of Economic Analyses, SGH Warsaw School of Economics, Warsaw, Poland.ORCID https://orcid.org/0000-0001-5068-0276
Dorota KrasowskaDepartment of Dermatology, Venereology and Pediatric Dermatology, Medical University of Lublin, Lublin, Poland.ORCID https://orcid.org/0000-0002-3176-9870

Funding

European Union from the European Social Fund
6 · The paper itself

Abstract

backgroundAlthough the data on psoriasis epidemiology included in the Global Psoriasis Atlas (GPA) provide valuable information on psoriasis prevalence worldwide, the GPA database is still incomplete. Therefore, the aim of the study was to assess the prevalence, incidence, and mortality rates of psoriasis and its types in Poland based on the data registered by the National Health Fund (NHF).

methodsThe study included psoriasis patients registered at least twice in the Polish NHF database between 2010 and 2023.

resultsAt the end of 2023, 639,662 living psoriasis patients had been registered in the Polish NHF database, which constituted 1.70% of the Polish general population. The percentage of female psoriasis patients was found to be higher (54.95%) than male patients (45.05%). Of all the Polish NHF-registered psoriasis patients, plaque psoriasis affected 95.66%, pustular psoriasis 3.05%, psoriatic arthritis 7.20%, and guttate psoriasis 0.27%. In comparison to the general Polish population, psoriasis prevalence was observed to be lower in children (0.84%). The all-cause mortality rate among psoriasis patients was found to be higher in comparison to the general Polish population, with a higher mortality rate noted in male psoriasis patients.

conclusionsThe NHF database we studied suggests a direct relationship between the prevalence, incidence, and all-cause mortality rates in psoriasis and patients' age and sex. However, the study also revealed a decrease in mortality rates and a slow increase in the prevalence of psoriasis in the Polish population, which calls for further studies.

Indexed as

PsoriasisAdolescentAdultAgedAged, 80 and overAge DistributionArthritis, PsoriaticChildChild, PreschoolDatabases, FactualFemaleHumansIncidenceInfantMaleMiddle Agedepidemiologygeneral dermatologyincidencemortalityPolandprevalencepsoriasis

Identifiers

PMID40390157
PMCPMC12332235

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.